Evidence map›Paper›PMID 37503294›Full record

ArticlemedRxiv : the preprint server for health sciences2023

A Preliminary Investigation Of Repetitive Transcranial Magnetic Stimulation Applied To The Left Dorsolateral Prefrontal Cortex In Treatment Seeking Participants With Cannabis Use Disorder.

Gregory L Sahlem, Bohye Kim, Nathaniel L Baker, Brendan L Wong, Margaret A Caruso, Lauren A Campbell, Irakli Kaloani, Brian J Sherman, Tiffany J Ford, Ahmad H Musleh and 8 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 2 institutions in 1 country.

Gregory L SahlemDepartment of Psychiatry and Behavioral Sciences, Stanford University, Palo Alto, California, USA.
Bohye KimDepartment of Psychiatry and Behavioral Sciences, Stanford University, Palo Alto, California, USA.
Nathaniel L BakerDepartments of Public Health Sciences, Medical University of South Carolina, Charleston, South Carolina, USA.
Brendan L WongDepartment of Psychiatry and Behavioral Sciences, Stanford University, Palo Alto, California, USA.
Margaret A CarusoDepartments of Psychiatry, Medical University of South Carolina, Charleston, South Carolina, USA.
Lauren A CampbellDepartments of Psychiatry, Medical University of South Carolina, Charleston, South Carolina, USA.
Irakli KaloaniDepartment of Psychiatry and Behavioral Sciences, Stanford University, Palo Alto, California, USA.
Brian J ShermanDepartments of Psychiatry, Medical University of South Carolina, Charleston, South Carolina, USA.
Tiffany J FordDepartment of Psychiatry and Behavioral Sciences, Stanford University, Palo Alto, California, USA.
Ahmad H MuslehDepartment of Psychiatry and Behavioral Sciences, Stanford University, Palo Alto, California, USA.
Jane P KimDepartment of Psychiatry and Behavioral Sciences, Stanford University, Palo Alto, California, USA.
Nolan R WilliamsDepartment of Psychiatry and Behavioral Sciences, Stanford University, Palo Alto, California, USA.
Andrew J ManettDepartments of Psychiatry, Medical University of South Carolina, Charleston, South Carolina, USA.
Ian H KratterDepartment of Psychiatry and Behavioral Sciences, Stanford University, Palo Alto, California, USA.
Edward B ShortDepartments of Psychiatry, Medical University of South Carolina, Charleston, South Carolina, USA.
Terese K KilleenDepartments of Psychiatry, Medical University of South Carolina, Charleston, South Carolina, USA.
Mark S GeorgeDepartments of Public Health Sciences, Medical University of South Carolina, Charleston, South Carolina, USA.
Aimee L McRae-ClarkDepartments of Public Health Sciences, Medical University of South Carolina, Charleston, South Carolina, USA.
Medical University of South Carolina · USStanford University · US

Funding

Clinical Scientists Training Program in Addictions at MUSCK12DA031794 · NIDA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI Kevin M. Gray, AIMEE L MCRAE-CLARK · 2013 to 2026
$7.2M
MID-CAREER AWARD IN PATIENT-ORIENTED DRUG ABUSE RESEARCHK24DA038240 · NIDA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI MCRAE-CLARK, AIMEE L · 2014 to 2023
$1.9M
A Preliminary Investigation of Pre-Frontal repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Cannabis Use DisorderK23DA043628 · NIDA · STANFORD UNIVERSITY · PI SAHLEM, GREGORY · 2017 to 2022
$933k
NIDA NIH HHS K12 DA031794NIDA NIH HHS K23 DA043628NIDA NIH HHS K24 DA038240
6 · The paper itself

Abstract

Background: Cannabis use disorder (CUD) is a common and consequential disorder. When applied to the dorsolateral prefrontal cortex (DLPFC), repetitive transcranial magnetic stimulation (rTMS) reduces craving across substance use disorders and may have a therapeutic clinical effect when applied in serial sessions. The present study sought to preliminarily determine whether serial sessions of rTMS applied to the DLPFC had a therapeutic effect in CUD. Methods: This study was a two-site, phase-2, double-blind, randomized-controlled-trial. Seventy-two treatment-seeking participants (37.5% Women, mean age 30.2±9.9SD) with ≥moderate-CUD were randomized to active or sham rTMS (Beam-F3, 10Hz, 20-total-sessions, with cannabis cues) while undergoing a three-session motivational enhancement therapy intervention. The primary outcome was the change in craving between pre- and post-treatment (Marijuana Craving Questionnaire Short-Form-MCQ-SF). Secondary outcomes included the number of weeks of abstinence and the number of days-per-week of cannabis use during 4-weeks of follow-up. Results: There were no significant differences in craving between conditions. Participants who received active rTMS reported numerically, but not significantly, more weeks of abstinence in the follow-up period than those who received sham rTMS (15.5%-Active; 9.3%-Sham; rate ratio = 1.66 [95% CI: 0.84, 3.28]; Conclusions: This trial suggests rTMS is safe and feasible in individuals with CUD and may have a therapeutic effect on frequency of cannabis use, though further study is needed with additional rTMS-sessions and a longer follow-up period.

Indexed as

addictioncannabisCannabis use disordermarijuanaTMStranscranial magnetic stimulation

Identifiers

PMID37503294
PMCPMC10370231
OpenAlexW4384024921

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.